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Background/Aims: Endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) remains the most common EUS-guided tissue 
acquisition technique. This study aimed to evaluate the performance of a new Franseen tip fine needle biopsy (FNB) device for EUS-
guided sampling of solid lesions and compare it with the historical FNA technique.
Methods: Acquire® 22 G FNB needle (Boston Scientific Co., Natick, MA, USA) was used for solid tumor sampling (Study group). 
Tissue was collected for rapid on-site evaluation, and touch and crush preparations were made. Historical EUS-FNA samples obtained 
using Expect® 22 G FNA needle (Boston Scientific Co.) were used as controls (Control group). All specimens were independently 
evaluated by two cytopathologists blinded to the formal cytopathological diagnosis.
Results: Mean cell block histology scores were significantly higher (p=0.046) in the FNB group (51 samples) despite a significantly 
lower (p<0.001) mean number of passes compared to the FNA group (50 specimens). The overall diagnostic yields for the FNB vs. FNA 
groups were 96% vs. 88%. The degree of tumor differentiation was adequately assessed in all cell block qualifying lesions in the FNB 
group. Two patients developed post-FNB abdominal pain.
Conclusions: The new Franseen tip FNB device provides histologically superior and cytologically comparable specimens to those 
obtained by FNA, but with fewer passes. Clin Endosc  2018;51:576-583
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INTRODUCTION
Endoscopic ultrasound-guided fine needle aspiration (EUS-
FNA) remains the most common EUS-guided tissue acquisi-
tion technique. However, its reported sensitivity ranges from 
65% to 95%.1,2 Several factors can influence the diagnostic 
yield of any EUS-guided sampling procedure, including the 
needle type and size, number of passes, lesion-specific charac-
teristics, such as location and size, and, finally, endosonogra-
pher’s experience.1,3,4 The presence of rapid on-site cytological 
evaluation (ROSE) can positively impact the outcome of an 
EUS-FNA procedure,5 although its overall impact on the 
diagnostic yield of malignant lesions has been recently chal-
lenged.6 The diagnostic yield of FNA has been consistently 
high in pancreatic solid lesions, exceeding 85%,7 but varies 
in subepitheial tumors, ranging from 45% to 90%.8,9 A newer 
generation of fine needle biopsy (FNB) needles became avail-
able in the recent years and helped improve the tissue yield 
compared to the first generation of Trucut biopsy needles.10-12 
A recent meta-analysis demonstrated comparable diagnostic 
yield to standard FNA needles with fewer passes.13 
This study aimed to evaluate the overall diagnostic perfor-
mance of a new FNB device with a Franseen tip equipped 
with three cutting edges for EUS sampling of solid lesions (Fig. 
1). We sought to assess the cytological and histological yield of 
the FNB samples compared to those of historical FNA sam-
Received: March 10, 2017    Revised: May 21, 2017 
Accepted: May 31, 2017
Correspondence: Mohammad Al-Haddad
Division of Gastroenterology, Section of Interventional Endoscopy, Indiana 
University School of Medicine, 550 University Blvd, Suite 4100, Indianapolis, IN 
46202, USA
Tel: +1-317-944-7896, Fax: +1-317-948-8144, E-mail: moalhadd@iu.edu
ORCID: https://orcid.org/0000-0003-1641-9976
cc  This is an Open Access article distributed under the terms of the Creative 
Commons Attribution Non-Commercial License (http://creativecommons.org/
licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, 
and reproduction in any medium, provided the original work is properly cited.
   577 
El Hajj II et al. Performance of a New FNB Needle
ples (controls) obtained using a similar size needle. Our sec-
ondary goals were to compare the number of passes required 
to achieve a cytopathological diagnosis by each method and 
to assess the cytological quality of smears prepared from FNB 
samples for immediate cytological interpretation. Finally, we 
report on the adverse events associated with the use of this 
new FNB device.
MATERIALS AND METHODS
Study design and study population
This single-center study was approved by the Indiana 
University School of Medicine Institutional Review Board. 
Consecutive patients referred to a single operator (MAH) for 
EUS-guided sampling of solid lesions were prospectively en-
rolled between September 2016 and March 2017. All patients 
underwent EUS-FNB. ROSE was available in all cases. Patients 
were excluded if no cell block material was collected or if no 
standard reference diagnosis was obtainable. 
Patient demographics and lesion-related characteristics, 
including the size and location of target lesions, cytological 
and pathological findings (in case of lesion surgical resection), 
and clinical outcomes, were recorded. FNB-related abstracted 
data included: smear cytology score, cell block histology score, 
number of passes for smears, number of additional passes for 
cell block, and total number of passes. 
EUS-FNA samples previously accrued from solid lesions by 
the same endosonographer (MAH) between 2013 and 2015 
using the Expect® 22 G FNA needle (Boston Scientific Co., 
Natick, MA, USA) were identified and used as controls. ROSE 
was available in all FNA cases, as this is the standard of care 
at our center, and was performed in the same way described 
below for the FNB group.
Matching of controls to cases was performed in two stages: 
first, consecutive samples obtained from solid lesions were 
included; subsequently, matching of cases and controls by 
site (pancreatic vs. non-pancreatic) was attempted. Only con-
trols with available cell block histology score and confirmed 
diagnosis were included using the same reference diagnostic 
standard of the Study (FNB) group. All specimens were inde-
pendently evaluated by two expert cytopathologists (SR and 
HW) to assess the cytological yield (on smears) and histologi-
cal yield (on cell block preparations) using a standard scoring 
system reached by a consensus among our cytopathologists 
prior to the launching of the study (Table 1, Figs. 2-6). The 
cytopathologists were blinded to the formal cytopathological 
diagnosis rendered for clinical care in all FNB cases and con-
trols. 
Study definitions
A clear, non-equivocal diagnosis of malignancy was based 
on neoplastic cyto-histopathology by endoscopic sampling 
(FNB or FNA) and/or surgical resection. When cytology was 
non-diagnostic, the diagnosis of malignancy was considered 
based on neoplastic EUS impression, clinical course, and im-
aging findings consistent with malignancy at ≥6 months of 
follow-up. 
EUS-FNB technique and ROSE
All procedures were performed by the same experienced 
endosonographer (MAH). EUS-FNB was performed using a 
linear array echoendoscope (Olympus America Inc., Center 
Valley, PA, USA) and a 22 G Acquire® FNB needle (Boston 
Scientific Co.). Monitored anesthesia care sedation was pro-
vided by anesthesiologists for all procedures. The slow-pull 
technique was used to remove the stylet and was followed 
Fig. 1. Pictures of the new Franseen tip fine needle biopsy (FNB) histology 
needle. (A) An image of the FNB needle. (B) Closer view of the tip of the FNB 
needle.
A B
Table 1. Cytological and Histological Scoring Systems Used in the Study
Scoring System Cytology criteria (smears) Histology criteria (cellblock)
Score 1 5 or fewer groups (≥10 cells each group) or <50 tumor 
cells for tumors with dishesive pattern
5 or fewer groups (≥10 cells each group) or <50 tumor 
cells for tumors with dishesive pattern
Score 2 6–10 groups (≥10 cells each group) or 50–100 tumor cells 
for tumors with dishesive pattern 
6–10 groups (≥10 cells each group) or 50–100 tumor 
cells for tumors with dishesive pattern
Score 3 >10 groups (≥10 cells each group) or >100 tumor cells for 
tumors with dishesive pattern
>10 groups (≥10 cells each group) or >100 tumor cells 
for tumors with dishesive pattern
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by application of 5 mL of negative pressure for 5–10 seconds, 
during which at least five additional actuations were per-
formed. The fanning technique was used whenever feasible. 
Following the needle withdrawal, obtained tissue was pro-
cessed on site, and touch preparations or crush smears were 
prepared. Slides were air-dried and stained with modified 
Wright Giemsa staining for ROSE. If the first smear was nega-
tive, the endosonographer performed additional smears until 
it turned positive, or it was felt that further sampling would 
not increase the smears yield. All additional visible cores were 
placed in a cellular preservative (CytoRich Red; Becton Dick-
inson, Franklin Lakes, NJ, USA) for cell block preparation. Vi-
sual inspection of the cell block was performed to ensure that 
there was sufficient material in terms of the cloudiness of the 
fluid, and not necessarily relying on the presence of defined 
whitish cores (some mini-cores can be hard to detect visually 
and turn the fluid turbid) (Fig. 7). 
Follow-up
Procedure-related outcomes were collected prospectively. 
Our endoscopy unit routinely telephones all patients within 
48–72 hours after the procedures to assess for short-term ad-
verse events. Adverse events were recorded according to the 
Fig. 3. Fine needle biopsy specimen obtained from a pancreatic body mass. 
This was assigned a score of 2 on cell block. The final diagnosis was pancreat-
ic adenocarcinoma (Hematoxylin and eosin, ×20).
Fig. 2. Fine needle biopsy specimen obtained from a pancreatic head mass. 
This lesion was sampled using standard fine needle aspiration technique twice 
prior to referral to our hospital with insufficient cytology. Rare malignant cells 
seen infiltrating the fibrous stroma. This was assigned a score of 1 on the cell 
block. The final diagnosis was pancreatic adenocarcinoma (Hematoxylin and 
eosin, ×100).
Fig. 4. Fine needle biopsy specimen obtained from a mediastinal mass. This 
was assigned a score of 3 on cell block. The final diagnosis was poorly differ-
entiated lung cancer (Hematoxylin and eosin, ×40).
Fig. 5. Fine needle aspiration specimen obtained from a liver mass. This was 
assigned a score of 3 on cell block. The final diagnosis was metastatic esopha-
geal cancer (Hematoxylin and eosin, ×40).
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criteria.14 Additional follow-up information after EUS was 
performed by review of medical charts and contact with the 
referring physicians (if necessary).
Data analysis
Continuous variables were reported as mean±standard de-
viation. Categorical variables were presented as numbers and 
percentages. Sensitivity, specificity, positive predictive value, 
negative predictive value, and accuracy were calculated. To 
determine the differences between the groups, the Student’s 
t-test was used for continuous variables and chi-squared 
or Fisher’s exact test was used for categorical variables. The 
sample size was not estimated a priori as this is the first study 
conducted with this novel needle. We chose 50 samples in the 
test group and a similar number of controls as a convenience 
sample. Two-sided p-values <0.05 were considered statistically 
significant. Statistical analysis was performed using SPSS 21.0 
software for Windows (SPSS Inc., Chicago, IL, USA).
RESULTS
Fifty patients (28 males) underwent EUS-FNB for 51 solid 
lesions between September 2016 and March 2017 at Indiana 
University Hospital and comprised the Study group. Lesion 
and sampling results characteristics are summarized in Table 
2. A neoplastic diagnosis was confirmed in the vast majority 
of patients (48/50; 96%) based on cytology. Resection surgical 
pathology confirmed the cytological diagnosis in 12 patients 
(24%). 
Fifty FNA specimens from solid lesions were pulled from 
our cytology archives and were independently reviewed 
(Control group). Mean cell block histology scores were signifi-
cantly higher in the FNB group (p=0.046) despite an overall 
lower mean number of passes compared to the FNA group 
(p<0.001, Table 2). The overall diagnostic yield of FNB was 
96% compared to 88% for the FNA group, but the difference 
did not reach statistical significance. 
The degree of tumor differentiation for primary tumors, 
origin of metastatic lesions, and mitotic index in neuroendo-
crine and stromal tumors (n=18) was adequately assessed in 
Fig. 6. (A) Fine needle biopsy specimen obtained from a gastric subepithelial mass. Extensive bands of spindled cells with high cellularity are noted in this cell block. 
The final diagnosis of gastrointestinal stromal tumor was confirmed on c-Kit staining (Hematoxylin and eosin [H&E], ×40). (B) Fine needle aspiration specimen pulled 
from the archives from a gastric subepithelial mass of similar morphology and dimensions to the one presented in (A). Although this preparation is still diagnostic for 
gastrointestinal stromal tumor, substantially fewer groups of spindled cells are noted in this cell block (H&E, ×40).
A B
Fig. 7. As opposed to the blood-tinged preservative solution with a clot on the 
bottom of the tube seen with standard fine needle aspiration cell blocks, fine 
needle biopsy blocks tend to be less bloody with several visible tan-colored 
tissue fragments (cores).
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all lesions based on cell block studies in the FNB group (Table 
3). The performance characteristics (sensitivity, specificity, and 
accuracy) of the two sampling methods assessed in this study 
(FNB vs. FNA) are summarized in Table 4.
Adverse events
All adverse events were classified as mild, and were recog-
nized during or immediately after the procedure.14 
Two patients (4%) developed post-procedural abdominal 
Table 3. Confirmed Clinical Outcomes of All 50 Patients Included in the Study
Site of FNB (n=51)a) Final reference diagnosis (n=50)a)
Pancreas (n=21)b)
   Head and Uncinate (n=11)
   Body (n=5)
   Tail  (n=5)
Adenocarcinoma (n=9); Chronic pancreatitis (n=1); NET (n=1)
Adenocarcinoma (n=4); Chronic pancreatitis (n=1); 
Adenocarcinoma (n=4); Well differentiated NET (n=1)
SET (n=8)
   Esophageal (n=3)
   Gastric (n=4)
   Duodenum (n=1)
Leiomyoma (n=3)
GIST (n=4)
GIST (n=1)
Lymph nodes (n=6) Metastatic adenocarcinoma (n=4); Large B cell lymphoma (n=1)
Metastatic melanoma (n=1)
Liver lesions (n=5) Metastatic adenocarcinoma (n=3); Metastatic NET (n=1); Metastatic melanoma (n=1)
Distal bile duct masses (n=3) Cholangiocarcinoma (n=3)
Mediastinal masses (n=2) Poorly differentiated carcinoma (n=1); Squamous cell carcinoma (n=1)
Retroperitoneal masses (n=2) Local recurrence of previously resected pancreatic adenocarcinoma (n=2)
Miscellaneous (n=4)
   Gastric wall thickening (n=1)
   Perirectal mass (n=1)
   Left adrenal mass (n=1) 
   Pelvic mass (n=1)
Adenocarcinoma (linitis plastica)
Local recurrence of previously resected rectal adenocarcinoma
Metastatic lung adenocarcinoma
Teratoma
FNB, fine needle biopsy; NET, neuroendocrine tumor; SET, subepitheial tumor; GIST, gastrointestinal stromal tumor.
a)A single patient with metastatic melanoma underwent sampling of liver lesion and a lymph node, both were metastatic.
b)Four patients diagnosed eventually with adenocarcinoma based on FNB had previous insufficient fine needle aspiration sampling at other 
institutions. 
Table 4. Performance Characteristics of the 2 Sampling Methods Assessed in This Study (FNB vs. FNA) 
Sensitivity (95% CI) Specificity (95% CI) Accuracy
FNB group 95.9% (86.02% to 99.50%) 100% (15.81% to 100.00%) 96%
FNA group 87.23% (74.26% to 95.17%) 100% (29.24% to 100.00%) 88%
FNB, fine needle biopsy; FNA, fine needle aspiration; CI, confidence interval.
Table 2. Lesion and Sampling Results Characteristics of the Fine Needle Biopsy and Fine Needle Aspiration Cohorts
Lesion and sampling characteristics FNB (n=51) FNA (n=50) p-value
Mean size (maximal dimension, cm) 2.98 2.90 NS
Location: Pancreatic (n) 23 20 NS
Non pancreatic (n) 28 30
Cytology scores of smears (mean) 2.75 2.86 NS
Number of passes for smears (mean) 2.07 2.44 0.056
Cell block histology score (mean) 2.32 2.02 0.046
Number of additional passes for cell block (mean) 0.74 1.68 <0.001
Total number of passes (mean) 2.88 3.82 <0.001
Overall diagnostic yield 96% 88% NS
FNB, fine needle biopsy; FNA, fine needle aspiration; NS, non significant.
   581 
El Hajj II et al. Performance of a New FNB Needle
pain after pancreas mass FNB (confirmed adenocarcinoma on 
cytology). This required extended observation in the recovery 
room for 3 hours in one patient and 23-hour admission to the 
hospital for observation and pain management in another pa-
tient. 
In two cases, a hematoma developed outside the gastric and 
duodenal walls during FNB of the pancreatic body (Fig. 8) and 
head masses, respectively. Both patients underwent 4 passes 
each. The hematomas were monitored for 10 minutes and ap-
peared stable on EUS. This did not result in clinically apparent 
adverse outcomes and both patients were discharged home 
after 90 minutes of observation without the need for further 
interventions. 
No other adverse event was reported during or immediately 
after the procedure and up to 72 hours of follow-up. 
DISCUSSION
EUS-FNB is increasingly performed to sample solid lesions, 
but is currently reserved to cases where FNA cytology fails 
or when tissue architecture is essential for the diagnosis.1 The 
performance of earlier Trucut core biopsy devices (QuickCore; 
Cook Medical, Limerick, Ireland) was suboptimal due to me-
chanical failures of its spring loading mechanism.15 A newer 
needle with unique reversed bevel design was released in 2011 
(ProCore; Cook Medical) and remains the most widely stud-
ied needle.13 Superior histologic yield has been demonstrated 
in one recent randomized study comparing the ProCore to 
the QuickCore needles.12 However, multiple studies failed to 
demonstrate the superiority of this needle for sampling ad-
equacy or diagnostic accuracy over conventional EUS-FNA 
needles.16 A recent meta-analysis of nine studies including 576 
patients demonstrated no significant difference in diagnostic 
adequacy (75 % vs. 89 %), diagnostic accuracy (85 % vs. 86 %), 
or rate of histological core specimen acquisition (78 % vs. 
77 %) between the ProCore and standard FNA needles.13 More 
recently, the performance of the ProCore needle was com-
pared to that of a newer core biopsy device with a novel fork-
tip with opposing bevel design and multiple cutting surfaces 
(SharkcoreTM; Medtronic, Minneapolis, MN, USA).17 In this 
study, the opposing bevel needle provided significantly higher 
sensitivity (71.1% vs. 90.1%) and overall accuracy (74% vs. 
92%) for discriminating malignant from benign solid pancre-
atic masses.
Our study aimed to assess another new core biopsy device 
with three cutting surfaces and a Franseen shaped tip. We 
demonstrated that this device provides a histologically su-
perior sample with fewer passes compared to conventional 
FNA needles of the same size. The superiority of FNB samples 
have been recently reported with the fork-tip device.18,19 The 
current study agrees with the results of those two studies from 
two perspectives: first, the novel needle tip design appears to 
be a significant factor enhancing tissue acquisition; second, 
this same tip design could carry a slightly higher risk for tissue 
trauma, resulting in bleeding and post-procedural pain. In our 
series, as opposed to the results reported by Rodrigues-Pinto 
et al.,19 bleeding was self-limited in all cases with no further 
interventions were needed. 
We have also demonstrated that the smears prepared from 
such needles do not appear to be inferior to FNA smears for 
rapid review purposes. This is likely due to the rather frag-
mented nature of the cores accrued, allowing sheets of cells to 
smear in thin layers to allow cytological interpretation wheth-
er on alcohol fixed or on-site dipped smears. 
A recent preliminary descriptive report on this needle 
demonstrated that diagnostic material for ROSE and histology 
could be obtained in 97% of patients.20 Our study demonstrat-
ed a higher diagnostic accuracy in the FNB group compared 
to FNA group, although the difference did not reach statistical 
significance. This may be related to the fact that we applied 
strict cytological criteria to assess smears and cell block spec-
imens which relied on manual counting of the smears and 
cell blocks. Since the majority of sampled lesions were solid 
pancreatic masses, we drew the conclusions that in such cases, 
three passes are sufficient for establishing the diagnosis with 
over 90% diagnostic adequacy.
The yield of EUS-guided tissue acquisition is influenced by 
many factors.1,3,4 In the current study, we attempted to stan-
dardize many of the variables known to impact the outcomes 
of sampling. For example, a standard FNB sampling technique 
was performed by the same endosonographer, using the same 
needle gauge and the same standard cytological processing 
techniques. In addition, the vast majority of lesions in our 
FNB cohort were unequivocally neoplastic, and the few with 
Fig. 8. A hematoma that developed between the gastric wall and the pancre-
atic neck after fine needle biopsy of a pancreatic body mass.
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negative cytology had sufficient follow-up to rule out a malig-
nant outcome. Finally, our cytopathology team has devised a 
scoring system that minimizes subjectivity in assessing cellu-
larity of smears and cell block material. This system relies on 
a manual count of the number of diagnostic cells (most com-
monly tumors) and not on the presence of any nucleated cell. 
Similar scoring systems have been developed with variable 
cell count brackets.21 
The diagnostic yield of FNA in pancreatic masses remains 
high, with a recent meta-analysis showing an EUS-FNA 
pooled sensitivity and specificity for diagnosing solid pancre-
atic neoplasms of 85% and 98%, respectively.22 Despite that, 
a recent cost-effectiveness analysis from the perspective of a 
third-party payer showed that FNB was more cost-effective 
than FNA in sampling both pancreatic and non-pancreatic 
masses.23 Our study demonstrates the utility of routine use of 
a core biopsy device for solid lesion sampling during EUS.
In addition, this technique appeared to be safe. All adverse 
events were classified as mild, and were recognized during 
or immediately after the procedure. Two patients developed 
post-procedural abdominal pain, and two patients developed 
hematoma outside the gastric and duodenal walls. No other 
adverse events were reported during or immediately after the 
procedure and up to 72 hours of follow-up. 
We recognize several limitations to our study. This was not 
a prospective randomized controlled study. Different solid le-
sions from different organs were prospectively sampled using 
the FNB needle only; thus, a direct comparison of the perfor-
mance of FNB to FNA needles for the same lesion(s) could 
not be assessed. An important part of the assessment of this 
new tissue acquisition device was to examine its performance 
for the purposes of ROSE. As has been endorsed by several 
studies and key opinion leaders, we continue to rely heavily 
on ROSE and hence we describe the utility of FNB devices in 
the context of ROSE. The natural next step is to assess its per-
formance without ROSE, but this study was an early clinical 
utility study. In our cohort we did not have sufficient number 
of patients to comment on the performance of this device in 
specific situations like lymphoma, gastrointestinal stromal 
tumor, or autoimmune pancreatitis. Finally, we have chosen 
smears and cell block technique instead of histological exam 
(typically submitted in formalin). Moreover, our sample size 
was relatively small, since this is the first study to assess this 
specific needle platform in a controlled fashion. This could 
have been underpowered to detect true differences between 
the FNB and FNA groups in diagnostic accuracy. Despite that, 
several endpoints, including the total number of passes and 
the number of passes dedicated to cell block, met the statisti-
cal significance. Finally, we confirmed the results of previous 
reports showing that FNB devices are overall associated with 
fewer number of passes.13 Additionally, we acknowledge that 
there may be a learning curve to using a new needle platform 
that was “mastered” during the span of the study. 
In conclusion, the new Franseen tip biopsy needle enables 
sufficient acquisition of histological-quality samples under 
EUS-guidance. Due to the availability of various sizes and the 
overall safety of such devices, an FNB exclusive approach to 
sampling all solid lesions appears feasible. Further studies are 
needed to characterize the performance of this device in le-
sions of various origins and locations. 
Note
An abstract of this study was accepted for poster presentation at the Di-
gestive Diseases Week, 2017, Washington, DC and at 2017 American College 
of Gastroenterology Annual Meeting in Orlando, FL, USA.
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